This study assessed the contributions of rising mortality, falling HIV incidence and sexual behaviour change to the decline in HIV prevalence in Zimbabwe. Comprehensive review and secondary analysis was conducted of national and local sources on trends in HIV prevalence, HIV incidence, mortality and sexual behaviour covering the period 1985–2007. Data from eastern Zimbabwe showed substantial rises in mortality during the 1990s, levelling off after 2000. Estimates of HIV incidence indicated that HIV incidence may have peaked in the early 1990s and fallen during the 1990s. Household survey data showed reductions in numbers reporting casual partners from the late 1990s and high condom use in non-regular partnerships between 1998 and 2007. These findings provide the first convincing evidence of an HIV decline accelerated by changes in sexual behaviour in a southern African country. However, in 2007, one in every seven adults in Zimbabwe was still infected with a life-threatening virus and mortality rates remained at crisis level.
Equity and HIV/AIDS
Developing countries like Malawi are calculating the cost of adhering to new World Health Organization (WHO) guidelines that recommend starting HIV-positive people on antiretroviral drugs (ARVs) sooner. Malawi is one of three African countries that have conducted WHO-supported feasibility studies to assess what adopting the new guidelines would mean, and has announced plans to roll out the new WHO guidelines by mid-2011, said Dr Frank Chimbwandira, head of the HIV and AIDS department in the Ministry of Health. According to the feasibility study, the number of people on treatment would rise by about 50%, which could double the cost of the national ARV programme in terms of additional personnel and equipment, and would probably also mean waiting lists at many clinics. Implementing the WHO guidelines would mean major changes to national treatment protocols: HIV-positive people would start taking ARVs at a much higher CD4 count of 350, regular CD4 count and viral load monitoring would be conducted, and potentially more expensive treatment regimens would be adopted - including phasing out the ARV, stavudine, which has been associated with increased side-effects.
In this report, Médecins Sans Frontières (MSF) notes that major funders now seem to be withdrawing HIV and AIDS funding to countries like Malawi, Mozambique, Zimbabwe, South Africa, Lesotho, Kenya, Uganda and the Democratic Republic of Congo. According to MSF, PEPFAR has flatlined its funding for 2009-2014 and as of 2008-9, further decreased its annual budget allocations for the coming years by extending the period to be covered with the same amount of money. The World Bank currently prioritises investment in health system strengthening and capacity building in planning and management over HIV-dedicated funding, thereby reducing their support for HIV and AIDS care. In addition, UNITAID is phasing out its funding for drugs and other medical commodity procurement through the Clinton Foundation. By 2012, funding for second-line anti-retrovirals (ARVs) and paediatric commodities should end in Zimbabwe, Mozambique, the Democratic Republic of Congo and Malawi. The Global Fund is also currently facing a serious funding shortfall. To compound the problem further, MSF adds that all current funding scenarios are inadequately reflecting demand, as none includes the additional resources required to implement the new World Health Organization guidelines on earlier treatment and improved drug regimens.
In this study, the main objectives were to establish the proportion of adolescents among children infected with human immunodeficiency virus (HIV) in Zimbabwe who receive HIV care and support, and what clinic staff perceive to be the main problems faced by HIV-infected children and adolescents. In July 2008, the researchers sent a questionnaire to all 131 facilities providing HIV care in Zimbabwe, requesting an age breakdown of the children (aged 0–19 years) registered for care and asking to identify the two major problems faced by younger children (0–5 years) and adolescents (10–19 years). Nationally, 115 (88%) facilities responded. Of the 98 (75%) that provided complete data, 196,032 patients were registered and 24,958 (13%) of them were children. The main problems for younger children were identified as malnutrition and lack of appropriate drugs (cited by 46% and 40% of clinics, respectively), while adolescents were most concerned about psychosocial issues and poor drug adherence (cited by 56% and 36%, respectively).
Two new studies have confirmed fears that the use of antiretroviral (ARV) drugs to prevent HIV could lead to drug resistance if inadvertently used by people who were already infected. The findings, presented at the International Microbicides Conference in the United States earlier in May, suggest that regular HIV testing would have to be an integral part of any prevention programme using ARVs. Prevention approaches incorporating ARVs are still being tested in clinical trials, but are thought to be among the most promising potential interventions against HIV. One approach, called pre-exposure prophylaxis (PrEP), would involve giving a daily dose of a single ARV drug to people who were HIV-negative but at high risk. This could be effective in preventing HIV, but if someone who is already infected is treated, this could raise the risk of developing resistant strains of the virus.
Community home-based care is the Botswana Government's preferred means of providing care for people living with HIV (PLHIV). However, primary (family members) or volunteer (community members) caregivers experience poverty, are socially isolated, endure stigma and psychological distress, and lack basic care-giving education. This study estimated the cost incurred in providing care for PLHIV through a stratified sample of 169 primary and volunteer caregivers drawn from eight community home-based care groups in four health districts in Botswana. The results show that the mean of the total monthly cost (explicit and indirect costs) incurred by the caregivers was US$90.45, while the mean explicit cost of care giving was US$65.22. This mean of the total monthly cost is about one and a half times the caregivers' mean monthly income of US$66 and more than six times the Government of Botswana's financial support to the caregivers. The study, therefore, concludes that as the cost of providing care services to PLHIV is very high, the Government of Botswana should substantially increase the allowances paid to caregivers and the support it provides for the families of the clients. The overall costs for such a programme would be quite low compared with the huge sum of money budgeted each year for health care and for HIV and AIDS.
This paper conducted four phase III and one phase IIb trials of women-initiated HIV prevention options in KwaZulu-Natal between 2003 and 2009. A total of 7,046 women participated, with HIV prevalence between 25% and 45% and HIV incidence ranging from 4.5-9.1% per year. Community benefits from the trial included education on HIV prevention, treatment and care and provision of ancillary care (such as pap smears, reproductive health care and referral for chronic illnesses). Social benefits included training of home-based caregivers and sustainable ongoing HIV prevention education through peer educator programmes. Several challenges were encountered, including manipulation by participants of their eligibility criteria in order to enrol in the trial. Women attempted to co-enrol in multiple trials to benefit from financial reimbursements and individualised care. The trials became ethically challenging when participants refused to take up referrals for care due to stigma, denial of their HIV status and inadequate health infrastructure. Lack of disclosure of HIV status to partners and family members was particularly challenging. The researchers concluded that conducting these five trials in a period of six years provided them with invaluable insights into trial implementation, community participation, recruitment and retention, provision of care and dissemination of trial results.
In collaboration with local stakeholders, this study designed and assessed a referral system to link persons diagnosed at a voluntary counselling and testing (VCT) clinic in a rural district in northern Tanzania with a government-run HIV treatment clinic in a nearby city. Two-part referral forms, with unique matching numbers on each side were implemented to facilitate access to the HIV clinic, and were subsequently reconciled to monitor the proportion of diagnosed clients who registered for these services, stratified by sex and referral period. Delays between referral and registration at the HIV clinic were calculated, and lists of non-attendees were generated to facilitate tracing among those who had given prior consent for follow up. The study found that referral uptake at the HIV clinic averaged 72% among men and 66% among women during the first three years of the national antiretroviral therapy (ART) programme, and gradually increased following the introduction of the transportation allowances and community escorts, but declined following a national VCT campaign. It concluded that the referral system reduced delays in seeking care, and enabled the monitoring of access to HIV treatment among diagnosed persons. Similar systems to monitor referral uptake and linkages between HIV services could be readily implemented in other settings.
South Africa has launched an extensive programme of HIV testing, treatment and prevention that United Nations officials say is the largest and fastest expansion of AIDS services ever attempted by any nation. In the past month alone the government has enabled 519 hospitals and clinics to dispense AIDS medicines, more than it had in all the years combined since South Africa began providing antiretroviral drugs to its people in 2004, according to this article. The government has trained the hundreds of nurses now prescribing the drugs — formerly the province of doctors — and will train thousands more so that each of the country’s 4,333 public clinics can dispense AIDS medicines. President Jacob Zuma has inaugurated a campaign to test 15 million of the country’s 49 million people for HIV by June 2011.
African church leaders met in Johannesburg in May 2010 to find common ground in response to HIV and AIDS. At the meeting, the church acknowledged that it has failed to react timeously and effectively to the challenge of AIDS. At the meeting, church leaders spoke out about the silence and judgmental stance that characterised their response to the HIV and AIDS epidemic. The church resolved to amend its ways.